Pearson GJ, Thanassoulis G, Anderson T, et al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol. 2021 Aug;37(8):1129-1150. doi: 10.1016/j.cjca.2021.03.016. Epub 2021 Mar 26. PMID: 33781847.
Collet JP, Thiele H, Barbato E, et al; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021 Apr 7;42(14):1289-1367. doi: 10.1093/eurheartj/ehaa575. Erratum in: Eur Heart J. 2021 May 14;42(19):1908. Erratum in: Eur Heart J. 2021 May 14;42(19):1925. Erratum in: Eur Heart J. 2021 May 13; PMID: 32860058.
Thygesen K, Alpert JS, Jaffe AS, et al; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018 Nov 13;138(20):e618-e651. doi: 10.1161/CIR.0000000000000617. Erratum in: Circulation. 2018 Nov 13;138(20):e652. PMID: 30571511.
Mehta SR, Bainey KR, Cantor WJ, et al; members of the Secondary Panel. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. Can J Cardiol. 2018 Mar;34(3):214-233. doi: 10.1016/j.cjca.2017.12.012. Epub 2017 Dec 19. PMID: 29475527.
Fihn SD, Gardin JM, Abrams J, et al; American College of Cardiology Foundation/American Heart Association Task Force. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012 Dec 18;126(25):e354-471. doi: 10.1161/CIR.0b013e318277d6a0. Epub 2012 Nov 19. Erratum in: Circulation. 2014 Apr 22;129(16):e463. PMID: 23166211.
Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012 Oct;33(20):2569-619. doi: 10.1093/eurheartj/ehs215. Epub 2012 Aug 24. PMID: 22922416.
2012 Writing Committee Members, Jneid H, Anderson JL, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2012 Aug 14;126(7):875-910. doi: 10.1161/CIR.0b013e318256f1e0. Epub 2012 Jul 16. PMID: 22800849.
Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011 Dec 6;124(23):2574-609. doi: 10.1161/CIR.0b013e31823a5596. Epub 2011 Nov 7. Erratum in: Circulation. 2012 Feb 28;125(8):e411. PMID: 22064598.
Abraham NS, Hlatky MA, Antman EM, et al; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2010 Dec 7;56(24):2051-66. doi: 10.1016/j.jacc.2010.09.010. PMID: 21126648.
Coronary artery disease (CAD) is also referred to as ischemic heart disease (IHD) and is usually due to atherosclerosis of a coronary artery. CAD can be classified as stable or unstable, depending on the clinical manifestations of the disease.
ClassificationTop
1. Classification of CAD:
1) Stable CAD (chronic coronary syndrome):
a) Stable angina pectoris.
b) Vasospastic angina (Prinzmetal variant angina).
c) Microvascular angina (syndrome X).
d) Angina associated with myocardial bridging of coronary arteries.
2) Acute coronary syndromes (ACSs).
2. ACS classification based on initial electrocardiographic (ECG) findings:
1) Non–ST-segment elevation ACS.
2) ST-segment elevation ACS.
3. ACS classification based on clinical manifestations, biochemical markers of myocardial necrosis, and ECG:
1) Unstable angina (UA).
2) Non–ST-segment elevation myocardial infarction (NSTEMI).
3) ST-segment elevation myocardial infarction (STEMI).
4) Unspecified myocardial infarction (MI). ECG abnormalities that do not allow an unequivocal diagnosis of ST-segment elevation: left bundle branch block (acute or preexisting), pacemaker rhythm, or infarction diagnosed on the basis of clinical and biochemical criteria, with ECG performed >24 hours after the onset of symptoms.
5) Sudden cardiac death.
4. Classification of MI based on the evolution of ECG features:
1) Q-wave MI.
2) Non–Q-wave MI.
Etiology and PathogenesisTop
1. Etiology of myocardial ischemia:
1) Most commonly myocardial ischemia is due to coronary atherosclerosis.
2) Less commonly myocardial ischemia is due to coronary artery spasm (Prinzmetal variant angina, illicit drug use [eg, cocaine], or discontinuation of nitrates), coronary artery embolism, vasculitis of the coronary arteries, metabolic disorders affecting the coronary arteries, anatomic defects of the coronary arteries, coronary artery injury, arterial thrombosis due to disorders of hemostasis, reduced oxygen supply in relation to demand (aortic stenosis or regurgitation, hypertrophic cardiomyopathy, carbon monoxide poisoning, decompensated thyrotoxicosis, long-standing hypotension [shock]), anemia, myocardial bridging), or aortic dissection.
2. Etiology of ACS: Imbalance between the myocardial oxygen demand and supply, most frequently due to occlusion of a coronary artery by a thrombus formed on a ruptured atherosclerotic plaque.
1) UA most frequently results from rupture of an eccentric plaque. The resulting thrombus reduces coronary blood flow but occlusion is not complete, so that myocardial necrosis does not occur.
2) NSTEMI is the result of a process similar to UA and is associated with elevation of troponin levels, indicating myocardial necrosis due to subendocardial ischemia.
3) In STEMI the thrombus usually causes a complete and sudden occlusion of a coronary artery. Necrosis starts to develop within 15 to 30 minutes of the cessation of blood flow and spreads from the subendocardium to the epicardium. The rate at which necrosis develops depends on diameter of the occluded artery and collateral circulation.
3. Myocardial injury versus MI: Myocardial injury is defined as elevation of cardiac troponin values >99th percentile. In some situations myocardial injury is associated with MI, as per the definitions specified in the table below (essentially, clinical markers of ischemia must be present; Table 1).
4. Distinction between type 1 and type 2 MI is of particular clinical importance. Although in both of these situations there is a mismatch between oxygen supply and demand, in type 1 MI this occurs secondarily to acute plaque rupture and thrombus formation. In type 2 MI there are many different causes of relative oxygen deficiency (Table 1). Owing to their different mechanisms, type 2 MIs are not amenable to the same antithrombotic therapies as are employed for ACSs. Another important fact is that type 2 MI (demand ischemia) does not exclude an underlying CAD, as patients with non–plaque rupture MIs may still be more susceptible to stresses in the setting of CADs.
TablesTop
Criteria for types 1 and 2 MIa | |
Type 1 |
MI caused by atherothrombotic event precipitated by plaque erosion or plaque rupture with thrombus formation |
Type 2 |
Ischemic myocardial injury, usually in the setting of coronary atherosclerosis, from oxygen supply-demand mismatch without plaque erosion or rupture (eg, sudden anemia, prolonged tachyarrhythmia, coronary artery spasm or dissection, shock) |
Criteria for type 3 MI | |
Sudden cardiac death with new ischemic ECG changes or ventricular fibrillation with symptoms suggestive of myocardial ischemia; death occurs before blood biomarkers can be obtained or before increases in biomarkers are identified | |
Criteria for types 4 and 5 MI (procedure-related MI within 48 hours after index procedure)b | |
Type 4a |
PCI-related MI |
Type 4b |
In-stent thrombosis documented angiographically or by the same criteria as type 1 MI |
Type 4c |
In-stent restenosis or restenosis after balloon angioplasty documented angiographically or by the same criteria as type 1 MI |
Type 5 |
CABG-related MI |
a Rise and fall of cardiac troponins with ≥1 troponin value >99th percentile of URL along with either new ischemic ECG changes, development of pathologic Q waves, symptoms of acute myocardial ischemia, imaging evidence of new wall motion abnormality or loss of viable myocardium, or angiographic identification of coronary thrombus. b Further specific criteria: Coronary procedure–related MI ≤48 hours after the index procedure with an elevation in cardiac troponin values >5 × >99th percentile of URL for type 4a MI, >10 × for type 5 MI in patients with normal values at baseline. Patients with elevated but stable or declining baseline values must meet the criterion of >5-fold (in type 4a) or >10-fold (in type 5) increase as well as have a change ≥20% from the baseline value. Patients must also have one of the following: new ischemic changes (type 4a MI only), new pathologic Q waves, imaging evidence of loss of viable myocardium, or angiographic findings of a procedure-related flow-limiting complication. | |
Adapted from Circulation. 2018;138(20):e618-e651. | |
CABG, coronary artery bypass graft; ECG, electrocardiography; MI, myocardial infarction; PCI, percutaneous coronary intervention; URL, upper reference limit. |